The Pegasus Pharmaceuticals’s R&D Group has developed a new version of its HeartVue 6S System which is designed specifically for the continuous monitoring of heart conditions in emergency room environments during surgical procedures or other critical conditions that require continuous, stringent heart monitoring.
This device, termed the HeartVue 6S ERM (emergency room monitoring) System, is based on the patented analysis of the heart’s electrical alternans of the PQRST complexes. This enhanced version with modified software of the company’s original monitoring device will provide an automated, topological 3D image of the heart’s electrical activity every 30 seconds.
The HeartVue 6S ERM System also provides real time control of the heart responses to treatments, surgical or diagnostic procedures and the administration of medications. This monitoring system will subsequently undergo a series of clinical tests in the coming months, the company said.